Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics (NQ: MRTX )

58.25 -0.55 (-0.94%)
Streaming Delayed Price Updated: 10:15 AM EDT, May 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 72,248
Open 58.37
Bid (Size) 58.20 (2)
Ask (Size) 58.37 (3)
Prev. Close 58.80
Today's Range 58.02 - 60.76
52wk Range 51.16 - 195.99
Shares Outstanding 51,623,193
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Expert Ratings for Mirati Therapeutics
Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022
Upgrades 
Via Benzinga

Performance

YTD
-61.42%
-61.42%
1 Month
-17.42%
-17.42%
3 Month
-35.75%
-35.75%
6 Month
-57.73%
-57.73%
1 Year
-61.37%
-61.37%

More News

Read More
Mirati Therapeutics's Return On Capital Employed Overview
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
Analyst Ratings for Mirati Therapeutics
Via Benzinga
Mirati Therapeutics: Q1 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Earnings Preview For Mirati Therapeutics
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Via InvestorPlace
Earnings Scheduled For February 28, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Deciphera's DCC-3116/KRAS Inhibitor Combo Shows Deeper, Longer Tumor Regressions In Preclinical Studies
Via Benzinga
Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why
Via Benzinga
Where Mirati Therapeutics Stands With Analysts
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Via Benzinga
Preview: Mirati Therapeutics's Earnings
Via Benzinga
56 Biggest Movers From Yesterday
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Mirati Therapeutics' Adagrasib Application Under FDA Review For Lung Cancer Setting
Via Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
51 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.